Avalyn Pharma Inc. (NASDAQ:AVLN) Receives $59.00 Average PT from Analysts

Avalyn Pharma Inc. (NASDAQ:AVLN) has received an average recommendation of “Buy” from the five brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating, two have assigned a buy rating and two have given a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $59.00.

AVLN has been the subject of a number of recent research reports. Evercore assumed coverage on shares of Avalyn Pharma in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $51.00 price objective for the company. Morgan Stanley assumed coverage on shares of Avalyn Pharma in a report on Tuesday, May 26th. They issued an “overweight” rating and a $53.00 target price for the company. Zacks Research upgraded shares of Avalyn Pharma to a “hold” rating in a report on Wednesday, May 27th. Guggenheim assumed coverage on shares of Avalyn Pharma in a report on Monday, May 25th. They issued a “buy” rating and a $80.00 target price for the company. Finally, Wall Street Zen upgraded shares of Avalyn Pharma to a “hold” rating in a report on Saturday, May 9th.

Avalyn Pharma Price Performance

Shares of NASDAQ:AVLN opened at $25.72 on Friday. Avalyn Pharma has a 52 week low of $25.05 and a 52 week high of $32.22.

Insider Buying and Selling

In related news, major shareholder Sr One Capital Management, Llc bought 555,555 shares of Avalyn Pharma stock in a transaction dated Friday, May 1st. The shares were acquired at an average cost of $18.00 per share, with a total value of $9,999,990.00. Following the completion of the transaction, the insider owned 2,186,562 shares in the company, valued at $39,358,116. The trade was a 34.06% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jill Carroll bought 277,778 shares of Avalyn Pharma stock in a transaction dated Friday, May 1st. The shares were bought at an average cost of $18.00 per share, for a total transaction of $5,000,004.00. Following the completion of the transaction, the director owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. This trade represents a 14.55% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.